Share on LinkedInShare on LinkedIn

ARTICLE · 22 APRIL 2019

Irish Pharmaceuticals – An Allegation Of Predatory Pricing

Dillon Eustace
Dillon Eustace
Contributor
Dillon Eustace

Dillon Eustace

Dillon Eustace is one of Ireland’s leading law firms focusing on asset management and investment...

View firm profile
Explore more from Dillon Eustace

Recently, pharmaceutical companies have rejected allegations that they have been pursuing "predatory pricing" for new medicines.

IrelandAntitrust/Competition Law

Recently, pharmaceutical companies have rejected allegations that they have been pursuing "predatory pricing" for new medicines. The National Centre for Pharmacoeconomics alleged that pharmaceutical companies were offering discounts of up to 40% and 60% in negotiations to bring their drugs to the market. This serves as a reminder to all companies, whether in the pharmaceutical industry or not, that it is important to be cognisant of competition law when carrying out business. The Competition and Consumer Protection Commission ("CCPC") is responsible for enforcing Irish and EU competition law. The relevant legislation in Ireland is the Competition Acts 2002 – 2017 (the "Acts") which reflects the Treaty on the Functioning of the European Union (the "TFEU"). The Acts prohibit anti-competitive behaviour such as the abuse of a dominant position that a company may hold in the market. Predatory pricing would constitute such an abuse. Predatory pricing is classed as selling

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from